Go through these in order and stop at the first one that applies. If you are reading this for someone else, answer for them.
And for anyone, someone who:
Routine follow-up is important even when the person feels well because high blood sugar, liver disease, or kidney disease may not cause early symptoms.
The timing of visits depends on the type of lipodystrophy and any existing complications.
Between routine visits, contact the care team if fat loss spreads quickly, thirst or urination increases, menstrual patterns change, abdominal swelling develops, or treatment side effects appear.
Medication changes should be made with the prescribing clinician rather than independently.
The article also says
Monitoring may include blood pressure, growth in children, body-fat changes, glucose or A1C, triglycerides, cholesterol, and liver tests.
Urine and kidney testing are particularly important for people with acquired partial lipodystrophy.
Imaging or specialist testing may be needed if liver disease, heart disease, or other complications are suspected.
People receiving metreleptin need ongoing specialist monitoring for treatment response and adverse effects.
Those using injectable medicines should have their injection sites examined and should review site-rotation technique.
Every sign above is quoted from the sofidex article on Acquired lipodystrophy. If you are not sure, err upward — it is always reasonable to be checked.